Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

190 - A reliable nomogram for predicting overall survival in patients with triple-negative breast cancer


24 Nov 2018


Poster display - Cocktail


Targeted Therapy

Tumour Site

Breast Cancer


Ming Wei Ma


Annals of Oncology (2018) 29 (suppl_9): ix8-ix12. 10.1093/annonc/mdy427


M.W. Ma1, N. Jing2, S.X. Gao3

Author affiliations

  • 1 Radiation Oncology, Peking University First Hospital, 100034 - Beijing/CN
  • 2 Radiation Oncology, Hospital of Shanxi Medical University, 100034 - Beijing/CN
  • 3 Radiotherapy Department, Peking University First Hospital, Beijing/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 190


Currently, there is no reliable nomogram to predict overall survival (OS) for patients with triple-negative breast cancer (TNBC). The purpose of this study was to develop a prognostic nomogram from a cohort of TNBC patients by correlating clinical characteristics and pathological parameters with OS.


We retrospectively analysed 242 eligible TNBC patients treated between 2009 and 2012 at our institution. Age, family history, menopause status, operative type, tumour size, tumour histological grade, the number of axillary metastatic lymph node, postoperative pathological TNM stage, vascular invasion, perineural invasion, CK5/6 expression status, Ki67 index, and E-cadherin expression status were analysed. Predictors were used in a multivariable logistic regression analysis to develop a nomogram that predicts OS. The predictive accuracy and discriminative ability of the nomogram were determined by the concordance index (C-index) with calibration curves, and the receiver operating characteristic (ROC) curves, respectively. Analyses were performed with SPSS and R statistical software packages.


The median follow-up time was 70.73 months (range, 7.20–95.93 months) and the median age was 51 years (range, 29–69 years). Of the study patients, 32.6%, 42.6%, and 24.8% had disease stage I, II, III, respectively. The 3- and 5-year OS for all patients were 86.5% (95% CI, 82.2–90.8%) and 81.1% (95% CI, 76.2–86.0%), respectively. Multivariate analyses demonstrated that age, tumour size, the number of axillary metastatic lymph nodes, and E-cadherin expression were independent risk factors for OS. These predictors were used in the nomogram to estimate the 3- and 5-year OS. Calibration curves for probabilities showed good agreement between prediction by the nomogram and actual observation (C-index = 0.821).


Using clinicopathological information, we produced a prognostic nomogram that accurately predicts the 3- and 5-year OS for patients with TNBC.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Xian-shu Gao.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.